Circio Holding ASA (CRNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Circio Holding ASA (CRNA) has a cash flow conversion efficiency ratio of 2.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-25.66 Million ≈ $-2.70 Million USD) by net assets (Nkr-12.40 Million ≈ $-1.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Circio Holding ASA for the company's overall valuation and market capitalisation.
Circio Holding ASA - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Circio Holding ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Circio Holding ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Circio Holding ASA ranked by their cash flow conversion efficiency. Explore CRNA operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SolGold PLC
TO:SOLG
|
-0.013x |
|
Relais Group Oyj
HE:RELAIS
|
-0.002x |
|
Hypothekarbank Lenzburg AG
SW:HBLN
|
-0.426x |
|
Korea No. 9 Special Purpose Acquisition Co. Ltd.
KQ:368770
|
0.092x |
|
LEXINFINTECH ADR/2 CL.A
F:1LFA
|
N/A |
|
Strike Energy Ltd
AU:STX
|
0.079x |
|
Aten International Co Ltd
TW:6277
|
0.034x |
|
Samji Electronics Co. Ltd
KQ:037460
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Circio Holding ASA (2020–2025)
The table below shows the annual cash flow conversion efficiency of Circio Holding ASA from 2020 to 2025. View CRNA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr-12.49 Million ≈ $-1.31 Million |
Nkr-45.82 Million ≈ $-4.82 Million |
3.668x | +13.21% |
| 2024-12-31 | Nkr-12.51 Million ≈ $-1.32 Million |
Nkr-40.53 Million ≈ $-4.27 Million |
3.240x | +257.97% |
| 2023-12-31 | Nkr-98.54 Million ≈ $-10.37 Million |
Nkr-89.20 Million ≈ $-9.39 Million |
0.905x | +102.13% |
| 2022-12-31 | Nkr2.57 Million ≈ $270.02K |
Nkr-108.84 Million ≈ $-11.45 Million |
-42.417x | -20647.19% |
| 2021-12-31 | Nkr417.73 Million ≈ $43.96 Million |
Nkr-85.40 Million ≈ $-8.99 Million |
-0.204x | +31.25% |
| 2020-12-31 | Nkr372.59 Million ≈ $39.21 Million |
Nkr-110.79 Million ≈ $-11.66 Million |
-0.297x | -- |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in hu… Read more